Leerink Partnrs Issues Negative Outlook for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Investment analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for shares of Agilent Technologies in a research note issued on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of $1.32 per share for the quarter, down from their prior forecast of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.56 EPS and FY2027 earnings at $6.63 EPS.

Several other equities research analysts have also recently issued reports on the company. Sanford C. Bernstein reduced their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Evercore ISI lifted their price objective on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Stifel Nicolaus reissued a “buy” rating and issued a $151.00 target price on shares of Agilent Technologies in a report on Monday, August 26th. TD Cowen increased their price objective on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, JPMorgan Chase & Co. reduced their target price on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a report on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $143.62.

Agilent Technologies Stock Up 0.1 %

Shares of A opened at $133.19 on Friday. Agilent Technologies has a 12-month low of $124.16 and a 12-month high of $155.35. The business’s 50 day moving average is $136.04 and its 200 day moving average is $136.41. The company has a current ratio of 2.09, a quick ratio of 1.58 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $38.27 billion, a PE ratio of 30.13, a price-to-earnings-growth ratio of 4.48 and a beta of 1.07.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.41 by $0.05. The company had revenue of $1.70 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The firm’s revenue was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.38 EPS.

Agilent Technologies Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be given a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, December 31st. This represents a $0.99 dividend on an annualized basis and a yield of 0.74%. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s payout ratio is currently 22.40%.

Insider Transactions at Agilent Technologies

In related news, SVP Dominique Grau sold 9,990 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 19.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Agilent Technologies

Several institutional investors have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its position in Agilent Technologies by 5.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares during the period. FMR LLC increased its stake in Agilent Technologies by 62.2% during the 3rd quarter. FMR LLC now owns 1,287,665 shares of the medical research company’s stock worth $191,193,000 after buying an additional 493,947 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new position in shares of Agilent Technologies in the third quarter valued at approximately $49,449,000. Marshall Wace LLP raised its stake in Agilent Technologies by 48.6% during the second quarter. Marshall Wace LLP now owns 957,128 shares of the medical research company’s stock worth $124,073,000 after purchasing an additional 313,155 shares during the period. Finally, Jennison Associates LLC boosted its holdings in Agilent Technologies by 63.3% in the 3rd quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock valued at $87,075,000 after purchasing an additional 227,431 shares during the last quarter. 87.42% of the stock is owned by hedge funds and other institutional investors.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.